Updates are available Correction dated 2022-12-02
Click to view Correction: https://doi.org/10.1038/s41416-022-02087-9
-
Authors
Dieci, Maria Vittoria http://orcid.org/0000-0002-3967-9861
Carbognin, Luisa
Miglietta, Federica
Canino, Fabio
Giorgi, Carlo Alberto
Cumerlato, Enrico
Amato, Ottavia
Massa, Davide
Griguolo, Gaia http://orcid.org/0000-0002-8782-4509
Genovesi, Elisa
Garufi, Giovanna
Giannarelli, Diana
Tornincasa, Antonio
Trudu, Lucia
Michieletto, Silvia
Saibene, Tania
Lo Mele, Marcello
Fassan, Matteo
Zarrilli, Giovanni
Piacentini, Federico
Bria, Emilio
Guarneri, Valentina
-
Funding
Funding for this research was provided by:
Istituto Oncologico Veneto (L02P03, L04P25, L04P11)
Università degli Studi di Padova (BIRD 2021, BIRD 2020, BIRD 2020, BIRD 2021)
Associazione Italiana per la Ricerca sul Cancro (22759)
- License Information
-
More Information
Article History
Received: 7 June 2022
Revised: 21 October 2022
Accepted: 27 October 2022
First Online: 17 November 2022
Change Date: 2 December 2022
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41416-022-02087-9
Ethics approval and consent to participate
: The study was approved by the ethics committee of participating centres, and all relevant ethical regulations have complied. Informed consent was obtained from all participants.
: Not applicable.
: MVD reports personal fees from Eli Lilly, MSD, Exact Sciences, Novartis, Pfizer, Seagen, outside the submitted work; FM reports personal fees from Roche, outside the submitted work; GG reports personal fees from Novartis, Eli Lilly, outside the submitted work; EB reports personal fees, non-financial support and other from MSD, AstraZeneca, Pfizer, Eli Lilly, BMS, Novartis and Roche; and grants from AstraZeneca and Roche, outside the submitted work; VG reports personal fees from Roche, Novartis, Eli Lilly, MSD, GSK, Gilead; outside the submitted work. The remaining authors declare no competing interests.
